Articles

Don't shoot the messenger—target their genome

More complete version of the Aedes aegypti mosquito genome could lead to new avenues for blocking the spread of insect-borne diseases
Written byKelsey Kaustinen
| 3 min read

Mosquitoes likely rank at or near the top of everyone's list of least favorite insects for their constant attacks in the warmer months, and they're a key culprit in the spread of disease. One species, Aedes aegypti, is found on six different continents, and is responsible for infecting “more than 400 million people each year with dangerous viral pathogens, including dengue, yellow fever, Zika and chikungunya,” according to a recent Nature article.

The genome of Ae. aegypt was first sequenced in 2007, but given the technological restraints at the time, the resulting genome was piecemeal and disorganized, according to a press release from The Rockefeller University. With only fragments to work with, the help the genome offered was minimal.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
Illustration of multiple three-dimensional patient-derived organoids suspended against a dark blue background, representing tumor models used in precision oncology research.
By combining organoid biology with precision automation, researchers developed a miniaturized organoid screening platform that could help speed personalized cancer treatment testing.
3D illustration of a membrane protein embedded within a lipid nanodisc, representing a native-like environment used for membrane protein stabilization and characterization.
Mass photometry supports membrane protein characterization by providing rapid insights into sample composition, purity, and molecular assembly.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue